Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Russell W Jenkins

Showing results (41-50 of 80) with videos related to

Pageof 8
Sort By:
Immunology|January 13, 2012
Differential regulation of acid sphingomyelinase in macrophages stimulated with oxidized low-density lipoprotein (LDL) and oxidized LDL immune complexes: role in phagocytosis and cytokine releaseJean-Philip Truman, Mohammed M Al Gadban, Kent J Smith, et al.
The Journal of Biological Chemistry|February 22, 2011
Regulation of CC ligand 5/RANTES by acid sphingomyelinase and acid ceramidaseRussell W Jenkins, Christopher J Clarke, Daniel Canals, et al.
JCI Insight|April 9, 2026
Loss of Tumor-Infiltrating Lymphocytes and Poor Response to Immunotherapy in IDH GOF Mutant MelanomaEmma Specht, Lakshmi Pakanati, Meng-Ju Wu, et al.
Molecular Therapy. Oncology|March 4, 2025
Use of patient-derived organotypic tumor spheroids for testing of viral vector gene therapy in combination with checkpoint blockadeAna Carolina M Domingues, Soraia B de Oliveira, Nayara G Tessarollo, et al.
Journal of Immunotherapy and Precision Oncology|May 22, 2023
Translational Studies Using the MALT1 Inhibitor (<i>S</i>)-Mepazine to Induce Treg Fragility and Potentiate Immune Checkpoint Therapy in CancerMauro Di Pilato, Yun Gao, Yi Sun, et al.
Human Gene Therapy|May 12, 2012
Safety study of adeno-associated virus serotype 2-mediated human acid sphingomyelinase expression in the nonhuman primate brainErnesto A Salegio, Lluis Samaranch, Russell W Jenkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2024
Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 TargetingMarco Ventin, Giulia Cattaneo, Shahrzad Arya, et al.
Neurobiology of Disease|October 17, 2025
Retention of lysosomal acid sphingomyelinase protects from Niemann-Pick DiseaseCameron A Beard, Kyra N Hermanson, Justin M Snider, et al.
Journal for Immunotherapy of Cancer|June 25, 2025
SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapyRyan J Sullivan, Anthony R Cillo, Robert L Ferris, et al.
Pigment Cell & Melanoma Research|September 6, 2025
LRP2 Expression in Melanoma Is Associated With a Transitory Cell State, Increased T Cell Infiltration, and Is Upregulated by IFNy SignalingMartin Q Rasmussen, Marie L Bønnelykke-Behrndtz, Camilla Merrild, et al.
Pageof 8

Showing results (41-50 of 80) with videos related to

Sort By:
Pageof 8
Immunology|January 13, 2012
Differential regulation of acid sphingomyelinase in macrophages stimulated with oxidized low-density lipoprotein (LDL) and oxidized LDL immune complexes: role in phagocytosis and cytokine releaseJean-Philip Truman, Mohammed M Al Gadban, Kent J Smith, et al.
The Journal of Biological Chemistry|February 22, 2011
Regulation of CC ligand 5/RANTES by acid sphingomyelinase and acid ceramidaseRussell W Jenkins, Christopher J Clarke, Daniel Canals, et al.
JCI Insight|April 9, 2026
Loss of Tumor-Infiltrating Lymphocytes and Poor Response to Immunotherapy in IDH GOF Mutant MelanomaEmma Specht, Lakshmi Pakanati, Meng-Ju Wu, et al.
Molecular Therapy. Oncology|March 4, 2025
Use of patient-derived organotypic tumor spheroids for testing of viral vector gene therapy in combination with checkpoint blockadeAna Carolina M Domingues, Soraia B de Oliveira, Nayara G Tessarollo, et al.
Journal of Immunotherapy and Precision Oncology|May 22, 2023
Translational Studies Using the MALT1 Inhibitor (<i>S</i>)-Mepazine to Induce Treg Fragility and Potentiate Immune Checkpoint Therapy in CancerMauro Di Pilato, Yun Gao, Yi Sun, et al.
Human Gene Therapy|May 12, 2012
Safety study of adeno-associated virus serotype 2-mediated human acid sphingomyelinase expression in the nonhuman primate brainErnesto A Salegio, Lluis Samaranch, Russell W Jenkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2024
Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 TargetingMarco Ventin, Giulia Cattaneo, Shahrzad Arya, et al.
Neurobiology of Disease|October 17, 2025
Retention of lysosomal acid sphingomyelinase protects from Niemann-Pick DiseaseCameron A Beard, Kyra N Hermanson, Justin M Snider, et al.
Journal for Immunotherapy of Cancer|June 25, 2025
SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapyRyan J Sullivan, Anthony R Cillo, Robert L Ferris, et al.
Pigment Cell & Melanoma Research|September 6, 2025
LRP2 Expression in Melanoma Is Associated With a Transitory Cell State, Increased T Cell Infiltration, and Is Upregulated by IFNy SignalingMartin Q Rasmussen, Marie L Bønnelykke-Behrndtz, Camilla Merrild, et al.
Pageof 8